Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Cheng, Xianzhong, Zhou, Rui, Xu, Xia, Guo, Wenwen, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882236/
https://www.ncbi.nlm.nih.gov/pubmed/31775908
http://dx.doi.org/10.1186/s13048-019-0594-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882236/
https://www.ncbi.nlm.nih.gov/pubmed/31775908
http://dx.doi.org/10.1186/s13048-019-0594-1

Ejemplares similares